Preston Noon
Director/Miembro de la Junta en ViTToria Biotherapeutics, Inc. .
Perfil
Preston Noon is currently working as a Director at viTToria Biotherapeutics, Inc. and as a Partner at Agent Capital LLC.
He holds a Master's degree in Business Administration from the University of Connecticut.
Cargos activos de Preston Noon
| Empresas | Cargo | Inicio |
|---|---|---|
Agent Capital LLC
 Agent Capital LLC Investment ManagersFinance Agent Capital LLC (Agent Capital) is a venture capital firm founded in 2017 by Geeta Vemuri. The firm is headquartered in Waltham, Massachusetts. | Inversor de Capital Privado | - |
ViTToria Biotherapeutics, Inc.
 ViTToria Biotherapeutics, Inc. BiotechnologyHealth Technology viTToria Biotherapeutics, Inc. is a gene-edited cell therapeutics company based in Philadelphia, PA. The company is developing novel CAR-T cell therapies using their proprietary Senza5 platform, which maximizes stemness, durability, and target cell cytotoxicity. The technology is exclusively licensed from the University of Pennsylvania and has pipeline applications in oncology and autoimmune diseases. The company was founded by Bruce A. Peacock and Nicholas Siciliano, with Nicholas Siciliano serving as CEO since incorporation. | Director/Miembro de la Junta | - |
Formación de Preston Noon.
| University of Connecticut | Masters Business Admin |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 2 |
|---|---|
Agent Capital LLC
Agent Capital LLC Investment ManagersFinance Agent Capital LLC (Agent Capital) is a venture capital firm founded in 2017 by Geeta Vemuri. The firm is headquartered in Waltham, Massachusetts. | Finance |
ViTToria Biotherapeutics, Inc.
ViTToria Biotherapeutics, Inc. BiotechnologyHealth Technology viTToria Biotherapeutics, Inc. is a gene-edited cell therapeutics company based in Philadelphia, PA. The company is developing novel CAR-T cell therapies using their proprietary Senza5 platform, which maximizes stemness, durability, and target cell cytotoxicity. The technology is exclusively licensed from the University of Pennsylvania and has pipeline applications in oncology and autoimmune diseases. The company was founded by Bruce A. Peacock and Nicholas Siciliano, with Nicholas Siciliano serving as CEO since incorporation. | Health Technology |
- Bolsa de valores
- Insiders
- Preston Noon
